Seragy launches with €12 million financing to advance quantitative biomarkers for neurodegenerative diseases
seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS®…